Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
ArriVent BioPharma's lung cancer drug hits a wall. The company's therapy, firmonertinib, failed to meet its primary endpoint of progression-free survival in previously untreated patients with advanced non-small cell lung cancer (NSCLC). NSCLC is the most prevalent form of lung cancer, representing roughly 85% of all cases.
ArriVent's firmonertinib misses the mark in late-stage lung cancer trial
ArriVent BioPharma's experimental lung cancer therapy has stumbled at a critical hurdle. The company announced that firmonertinib failed to meet its primary endpoint — progression-free survival — in a late-stage trial involving previously untreated patients with advanced non-small cell lung cancer (NSCLC). The news sent the company's shares into a trading halt in premarket activity.
NSCLC is the dominant form of lung cancer, accounting for approximately 85% of all lung cancer diagnoses, making it a high-stakes therapeutic target for drugmakers worldwide.
By the Numbers
Why it matters: A Phase 3 failure in NSCLC is a significant setback — both for ArriVent and for patients hoping for new first-line treatment options. With NSCLC representing the vast majority of lung cancer cases globally, the search for effective therapies remains urgent, and this result narrows the near-term pipeline for this patient population.
